Bladder cancer is one of the most common urinary tumors. About 70% of the cases are non-muscle invasive bladder cancer (NMIBC) at the time of initial diagnosis while the recurrence rate is as high as 31% to 78% within 5 years. Furthermore, 17% to 45% of the patients will develop muscle-invasive bladder cancer (MIBC) later. At present, the traditional chemical drugs and BCG intravesical therapy can no longer meet the clinical needs, and some systematic treatments have been applied to the patients with BCG failure. In recent years, a variety of new intravesical therapies, including immune gene therapy, photodynamic treatment and new combination of drugs and equipment, have been put into clinical applications. This article will review the novel research progress and provide a new direction for the treatment of NMIBC.